Malaria

Published in the prestigious International Journal of Biological Macromolecules, the study, led by Dr Anand Ranganathan and Shailja Singh of JNU's Special Centre for Molecular Medicine, reveals that targeting Hsp70 could help prevent drug resistance, which is becoming a major issue in infection treatment.

The vaccine was developed by the Jenner Institute at Oxford University and Serum Institute of India with support from the European and Developing Countries Clinical Trials Partnership (‘EDCTP’), the Wellcome Trust, and the European Investment Bank (‘EIB’).

Gavi, the vaccine alliance, to provide 18 million doses of malaria vaccine to African countries. Bharat Biotech and Serum Institute of India are going to be the manufacturers in the global effort.

Dr Anand Ranganathan's team collaborated with another group headed by Shailaja Singh and Nishant Joshi at Shiv Nadar University for the study.